Cargando…
Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation.
Recent studies support the potential application of the wt-p53 gene in cancer therapy. Expression of exogenous wt-p53 suppresses a variety of leukaemia phenotypes by acting on cell survival, proliferation and/or differentiation. As for tumour gene therapy, the final fate of the neoplastic cells is o...
Autores principales: | Rizzo, M. G., Zepparoni, A., Cristofanelli, B., Scardigli, R., Crescenzi, M., Blandino, G., Giuliacci, S., Ferrari, S., Soddu, S., Sacchi, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150178/ https://www.ncbi.nlm.nih.gov/pubmed/9652758 |
Ejemplares similares
-
p53 as a unique target of action of cisplatin in acute leukaemia cells
por: Kumar, Sanjay, et al.
Publicado: (2022) -
Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
por: Uttenthal, Benjamin, et al.
Publicado: (2014) -
p53 status of newly established acute myeloid leukaemia cell lines
por: Zheng, A, et al.
Publicado: (1999) -
Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia
por: Zhu, Y-M, et al.
Publicado: (1999) -
Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer
por: Carter, Julia H., et al.
Publicado: (2018)